Sumary of Pfizer, US ink $5.29B deal for possible COVID-19 treatment:
- The U.S. government will pay drugmaker Pfizer $5.29 billion for 10 million treatment courses of its potential COVID-19 treatment if regulators authorize it.
- The U.S. has already agreed to pay roughly $700 per course of Merck’s drug for about 1.7 million treatments.
- -backed group to allow generic drugmakers to produce low-cost versions of the pill for certain countries.
- Pfizer reported earlier this month that its pill cut hospitalizations and deaths by 89% among high-risk adults who had early symptoms of COVID-19. The company studied its pill in people who were unvaccinated and faced the worst risks from the virus due to age or health problems, such as obesity.
- Pfizer wants the drug available for adults who have mild-to-moderate COVID-19 infections and are at risk of becoming seriously ill.
- But all FDA-authorized COVID-19 treatments require an IV or injection given by a health professional at a hospital or clinic.